BETRF BetterLife Pharma Inc. IFRS
Pharmaceutical Preparations · OTC · SEC CIK 1464165 · Reporting currency CAD · Fiscal year ends 01/31
Financial factors as of 2025-01-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2025*2025-01-31 | FY2024*2024-01-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | 424,337 | 570,947 |
| SG&A expense | 260,500 | 271,731 |
| Operating income | -5.00M | -3.24M |
| Interest expense | 165,087 | 45,544 |
| Pretax income | — | -2.90M |
| Net income | -3.52M | -2.89M |
| EBITDA | -5.00M | -3.24M |
| EPS (diluted) | -0.03 | -0.03 |
| Balance sheet | ||
| Cash & equivalents | 8,180 | 37,384 |
| Receivables | 11,644 | 39,536 |
| Total assets | 224,963 | 324,746 |
| Current liabilities | 7.54M | 7.35M |
| Short-term debt | — | 50,052 |
| Long-term debt | — | 49,115 |
| Total debt | — | 99,167 |
| Total liabilities | 7.59M | 8.02M |
| Shareholders' equity | -10.68M | -10.81M |
| Net debt | — | 61,783 |
| Shares outstanding | 43.49M | 52.81M |
| Cash flow statement | ||
| Operating cash flow | -2.02M | -2.47M |
| Financing cash flow | 1.99M | 2.50M |
| Depreciation & amortization | 0 | 0 |
| Stock-based compensation | 2.05M | 500,263 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.